GlassScriptPhysician profile
Cindy Wassef
NPI 1346669686
$1,144.77
in general payments reported to CMS, 2019-2025
24 companies · $445 in 2025
The $445 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.24 · 2020: $40.67 · 2021: $31.82 · 2022: $75.32 · 2023: $197 · 2024: $266 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.74 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $212.26 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $202.93 | 2019-2025 | |
| Abbvie INC. | $83.58 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $74.35 | 2023-2024 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $63.92 | 2022-2024 | Sotyktu |
| Ucb, INC. | $57.97 | 2022-2024 | Bimzelx |
| Galderma Laboratories, L.P. | $54.69 | 2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $49.77 | 2023 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $44.24 | 2025 | |
| Merck Sharp & Dohme LLC | $37.04 | 2025 | Capvaxive, Gardasil 9, Lagevrio |
| Lilly USA, LLC | $34.70 | 2024-2025 | Jardiance, Taltz |
| Amgen INC. | $22.38 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.15 | 2025 | Spevigo |
| Baxter Healthcare | $20.76 | 2022 | |
| Glaxosmithkline, LLC. | $19.82 | 2025 | Trelegy Ellipta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $19.41 | 2025 | Korlym |
| Radius Health, INC. | $18.89 | 2025 | Tymlos |
| Genzyme Corporation | $17.71 | 2023 | |
| Dermavant Sciences, INC. | $17.14 | 2023 | Vtama |
| Organon LLC | $16.84 | 2025 | Vtama |
| Leo Pharma INC. | $14.99 | 2025 | Spevigo |
| Pierre Fabre Pharmaceuticals, INC. | $14.57 | 2024 | Hemangeol |
| Celgene Corporation | $14.57 | 2024 | Sotyktu |
| Biofrontera INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Wassef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.